SK283089B6 - Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie - Google Patents
Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie Download PDFInfo
- Publication number
- SK283089B6 SK283089B6 SK1511-98A SK151198A SK283089B6 SK 283089 B6 SK283089 B6 SK 283089B6 SK 151198 A SK151198 A SK 151198A SK 283089 B6 SK283089 B6 SK 283089B6
- Authority
- SK
- Slovakia
- Prior art keywords
- burgdorferi
- mice
- ospa
- scid
- antibodies
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract description 10
- 208000016604 Lyme disease Diseases 0.000 title abstract description 4
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 44
- 241000699670 Mus sp. Species 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 241000448699 Borrelia burgdorferi ZS7 Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 3
- 244000000010 microbial pathogen Species 0.000 claims description 2
- 230000007918 pathogenicity Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 28
- 108091007433 antigens Proteins 0.000 abstract description 28
- 102000036639 antigens Human genes 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 18
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 108700006640 OspA Proteins 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000945 filler Substances 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000001503 joint Anatomy 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 244000005700 microbiome Species 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000238876 Acari Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010040721 Flagellin Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000589970 Spirochaetales Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000276440 Borrelia burgdorferi B31 Species 0.000 description 3
- 206010062746 Carditis Diseases 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000021646 inflammation of heart layer Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001288713 Escherichia coli MC1061 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000238681 Ixodes Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940099789 ospa protein Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SNKDCTFPQUHAPR-UHFFFAOYSA-N 1-fluoropyrimidine-2,4-dione Chemical compound FN1C=CC(=O)NC1=O SNKDCTFPQUHAPR-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 108010090127 Periplasmic Proteins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3931236 | 1989-09-19 | ||
| DE4015911A DE4015911A1 (de) | 1989-09-19 | 1990-05-17 | Impfstoff gegen die lyme-krankheit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK151198A3 SK151198A3 (en) | 1999-04-13 |
| SK283089B6 true SK283089B6 (sk) | 2003-02-04 |
Family
ID=25885304
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1511-98A SK283089B6 (sk) | 1989-09-19 | 1990-09-19 | Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie |
| SK1510-98A SK283088B6 (sk) | 1989-09-19 | 1990-09-19 | Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén |
| SK4560-90A SK456090A3 (en) | 1989-09-19 | 1990-09-19 | Vaccine against lyme disease and method for producing the same |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1510-98A SK283088B6 (sk) | 1989-09-19 | 1990-09-19 | Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén |
| SK4560-90A SK456090A3 (en) | 1989-09-19 | 1990-09-19 | Vaccine against lyme disease and method for producing the same |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US5178859A (ja) |
| EP (5) | EP0643974B1 (ja) |
| JP (3) | JP3205932B2 (ja) |
| KR (2) | KR100205462B1 (ja) |
| AT (4) | ATE191499T1 (ja) |
| AU (1) | AU651560B2 (ja) |
| CA (1) | CA2025597C (ja) |
| CZ (2) | CZ284538B6 (ja) |
| DE (5) | DE4015911A1 (ja) |
| DK (4) | DK0418827T3 (ja) |
| ES (4) | ES2082812T3 (ja) |
| FI (1) | FI102248B1 (ja) |
| GR (3) | GR3018995T3 (ja) |
| HK (2) | HK1002405A1 (ja) |
| HR (1) | HRP940545B1 (ja) |
| HU (2) | HU212716B (ja) |
| IE (1) | IE903377A1 (ja) |
| NO (2) | NO311767B1 (ja) |
| NZ (1) | NZ235260A (ja) |
| PL (2) | PL170229B1 (ja) |
| PT (1) | PT95349B (ja) |
| SI (1) | SI9011773B (ja) |
| SK (3) | SK283089B6 (ja) |
| YU (2) | YU48250B (ja) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US6143872A (en) * | 1988-10-24 | 2000-11-07 | Symbicom Aktiebolag | Borrelia burdorferi Osp A and B proteins and immunogenic peptides |
| US7094391B1 (en) * | 1988-10-24 | 2006-08-22 | The University Of Texas System | Compositions and methods for administering Borrelia burgdorferi antigens |
| US5777095A (en) * | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
| DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
| US5582829A (en) * | 1990-04-05 | 1996-12-10 | Rx Technologies, Inc. | Sonicated borrelia burgdorferi vaccine |
| SG47447A1 (en) | 1990-06-15 | 1998-04-17 | Univ Yale | Compositions and methods for the prevention and diagnosis of lyme disease |
| ATE196425T1 (de) * | 1990-07-06 | 2000-10-15 | American Home Prod | Impfstoff gegen die lyme-krankheit |
| CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
| US6872550B1 (en) | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
| US6221363B1 (en) * | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
| US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
| EP0877085A1 (en) * | 1991-08-15 | 1998-11-11 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines |
| WO1993008299A1 (en) * | 1991-10-18 | 1993-04-29 | Connaught Laboratories Inc. | Preparation of recombinant borrelia proteins |
| EP0540457A1 (en) * | 1991-10-22 | 1993-05-05 | Symbicom Ab | Improvements in Borrelia burgdorferi diagnosis and prophylaxis |
| US6303129B1 (en) * | 1992-07-28 | 2001-10-16 | Rx Technologies | Production of borrelia burgdorferi vaccine, product produced thereby and method of use |
| US5656451A (en) * | 1993-07-30 | 1997-08-12 | Yale University | OspE, OspF, and S1 polypeptides in borrelia burgdorferi |
| US6716591B1 (en) | 1993-07-30 | 2004-04-06 | Yale University | B. burgdorferi polypeptides |
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US5558993A (en) * | 1994-06-17 | 1996-09-24 | The Regents Of The University Of California | Cloned Borrelia burgdorferi virulence protein |
| GB9511909D0 (en) * | 1995-06-12 | 1995-08-09 | Microbiological Res Authority | Vaccine |
| US6437116B1 (en) | 1996-02-21 | 2002-08-20 | Board Of Regents, The University Of Texas System | VMP-like sequences of pathogenic borrelia |
| DE19632862B4 (de) | 1996-08-14 | 2006-08-03 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe |
| US6458555B1 (en) * | 1996-08-21 | 2002-10-01 | Gerd Bach | Cytologic method of examining mucous membranes |
| US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| DE19740735A1 (de) * | 1997-09-16 | 1999-03-18 | Max Planck Gesellschaft | Arzneimittel zur Therapie einer manifesten Lyme-Borreliose |
| US6306623B1 (en) * | 1998-02-24 | 2001-10-23 | The University Of California | Leptospiral major outer membrane protein LipL32 |
| WO2000006745A1 (en) | 1998-07-31 | 2000-02-10 | Gundersen Lutheran Medical Foundation, Inc. | Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine |
| WO2000056298A2 (en) * | 1999-03-19 | 2000-09-28 | Luitpold Pharmaceuticals, Inc. | Treatment of lyme disease with polysulfated glycosaminoglycan formulations |
| WO2000078345A1 (en) * | 1999-06-21 | 2000-12-28 | Milkhaus Laboratory, Inc. | Method for treatment of lyme disease |
| ES2298249T3 (es) | 2000-08-18 | 2008-05-16 | Research Foundation Of State University Of New York | Ospa modificada de borrelia burgdorferi. |
| US7847084B2 (en) | 2002-12-20 | 2010-12-07 | Board Of Regents, The University Of Texas System | VMP-like sequences of pathogenic Borrelia species and strains |
| SG176451A1 (en) | 2006-11-03 | 2011-12-29 | Schering Plough Ltd | Canine lyme disease vaccine |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| EP2167536A1 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| CA2781110C (en) * | 2009-11-17 | 2018-07-31 | Abaxis, Inc. | Peptides and methods for the detection of lyme disease antibodies |
| US8758772B2 (en) | 2011-11-04 | 2014-06-24 | Abaxis, Inc. | Peptides and methods for the detection of lyme disease antibodies |
| PL223175B1 (pl) | 2012-10-22 | 2016-10-31 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie |
| US9610336B1 (en) * | 2014-07-16 | 2017-04-04 | Amiram Katz | Immunotherapy for lyme disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US4772464A (en) | 1985-08-01 | 1988-09-20 | Miles Laboratories, Inc. | Protective antibodies to serotypic determinants of flagellar antigens |
| US4888276A (en) | 1986-06-26 | 1989-12-19 | Minnesota Mining And Manufacturing Company | Method and composition for the diagnosis of Lyme disease |
| US4721617A (en) | 1986-08-14 | 1988-01-26 | Regents Of The University Of Minnesota | Vaccine against lyme disease |
| US5034515A (en) * | 1987-09-22 | 1991-07-23 | Wisconsin Alumni Research Foundation | Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use |
| DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
| WO1991009870A1 (de) * | 1989-12-22 | 1991-07-11 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff |
| SG47447A1 (en) * | 1990-06-15 | 1998-04-17 | Univ Yale | Compositions and methods for the prevention and diagnosis of lyme disease |
| ATE196425T1 (de) * | 1990-07-06 | 2000-10-15 | American Home Prod | Impfstoff gegen die lyme-krankheit |
| CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
| EP0877085A1 (en) * | 1991-08-15 | 1998-11-11 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines |
| WO1993004157A1 (en) * | 1991-08-27 | 1993-03-04 | Novo Nordisk A/S | Detergent compositions |
| WO1993008299A1 (en) * | 1991-10-18 | 1993-04-29 | Connaught Laboratories Inc. | Preparation of recombinant borrelia proteins |
| WO1993007897A1 (en) * | 1991-10-21 | 1993-04-29 | Medimmune, Inc. | Bacterial expression vectors containing dna encoding secretion signals of lipoproteins |
-
1990
- 1990-05-17 DE DE4015911A patent/DE4015911A1/de not_active Withdrawn
- 1990-09-07 HU HU905816A patent/HU212716B/hu not_active IP Right Cessation
- 1990-09-11 NZ NZ235260A patent/NZ235260A/xx unknown
- 1990-09-12 AU AU62444/90A patent/AU651560B2/en not_active Ceased
- 1990-09-18 EP EP94112143A patent/EP0643974B1/de not_active Expired - Lifetime
- 1990-09-18 AT AT94112144T patent/ATE191499T1/de not_active IP Right Cessation
- 1990-09-18 ES ES90117943T patent/ES2082812T3/es not_active Expired - Lifetime
- 1990-09-18 AT AT90117943T patent/ATE131732T1/de not_active IP Right Cessation
- 1990-09-18 DE DE59010863T patent/DE59010863D1/de not_active Expired - Fee Related
- 1990-09-18 SI SI9011773A patent/SI9011773B/sl not_active IP Right Cessation
- 1990-09-18 EP EP90117943A patent/EP0418827B1/de not_active Expired - Lifetime
- 1990-09-18 ES ES94112143T patent/ES2129551T3/es not_active Expired - Lifetime
- 1990-09-18 AT AT94112143T patent/ATE175576T1/de not_active IP Right Cessation
- 1990-09-18 DE DE59010888T patent/DE59010888D1/de not_active Expired - Fee Related
- 1990-09-18 IE IE337790A patent/IE903377A1/en not_active IP Right Cessation
- 1990-09-18 DK DK90117943.2T patent/DK0418827T3/da active
- 1990-09-18 PL PL90307358A patent/PL170229B1/pl not_active IP Right Cessation
- 1990-09-18 DE DE59009978T patent/DE59009978D1/de not_active Expired - Fee Related
- 1990-09-18 AT AT94112145T patent/ATE186646T1/de not_active IP Right Cessation
- 1990-09-18 CA CA002025597A patent/CA2025597C/en not_active Expired - Fee Related
- 1990-09-18 EP EP94112144A patent/EP0633313B1/de not_active Expired - Lifetime
- 1990-09-18 DK DK94112144T patent/DK0633313T3/da active
- 1990-09-18 EP EP94112145A patent/EP0633028B1/de not_active Expired - Lifetime
- 1990-09-18 ES ES94112144T patent/ES2145077T3/es not_active Expired - Lifetime
- 1990-09-18 NO NO19904062A patent/NO311767B1/no unknown
- 1990-09-18 YU YU177390A patent/YU48250B/sh unknown
- 1990-09-18 DK DK94112145T patent/DK0633028T3/da active
- 1990-09-18 DK DK94112143T patent/DK0643974T3/da active
- 1990-09-18 DE DE59010903T patent/DE59010903D1/de not_active Expired - Fee Related
- 1990-09-18 EP EP98105444A patent/EP0861664A3/de not_active Withdrawn
- 1990-09-18 PL PL90286918A patent/PL169804B1/pl not_active IP Right Cessation
- 1990-09-18 FI FI904597A patent/FI102248B1/fi not_active IP Right Cessation
- 1990-09-18 ES ES94112145T patent/ES2141182T3/es not_active Expired - Lifetime
- 1990-09-19 JP JP24765090A patent/JP3205932B2/ja not_active Expired - Fee Related
- 1990-09-19 SK SK1511-98A patent/SK283089B6/sk unknown
- 1990-09-19 CZ CS904560A patent/CZ284538B6/cs not_active IP Right Cessation
- 1990-09-19 US US07/585,310 patent/US5178859A/en not_active Expired - Lifetime
- 1990-09-19 CZ CZ95970A patent/CZ284616B6/cs not_active IP Right Cessation
- 1990-09-19 KR KR1019900014814A patent/KR100205462B1/ko not_active IP Right Cessation
- 1990-09-19 PT PT95349A patent/PT95349B/pt active IP Right Grant
- 1990-09-19 SK SK1510-98A patent/SK283088B6/sk unknown
- 1990-09-19 SK SK4560-90A patent/SK456090A3/sk unknown
-
1993
- 1993-05-27 US US08/068,063 patent/US5434077A/en not_active Expired - Fee Related
-
1994
- 1994-09-15 HR HR940545A patent/HRP940545B1/xx not_active IP Right Cessation
-
1995
- 1995-03-20 US US08/406,623 patent/US5780030A/en not_active Expired - Fee Related
- 1995-03-20 US US08/407,350 patent/US5686267A/en not_active Expired - Lifetime
- 1995-04-24 HU HU95P/P00108P patent/HU211228A9/hu unknown
-
1996
- 1996-02-14 GR GR960400397T patent/GR3018995T3/el unknown
-
1997
- 1997-03-12 YU YU9097A patent/YU49370B/sh unknown
-
1998
- 1998-02-13 HK HK98101147A patent/HK1002405A1/xx not_active IP Right Cessation
- 1998-02-23 US US09/027,843 patent/US5856447A/en not_active Expired - Fee Related
- 1998-08-29 KR KR1019980035375A patent/KR100202128B1/ko not_active IP Right Cessation
- 1998-12-23 HK HK98114958A patent/HK1013620A1/xx not_active IP Right Cessation
-
1999
- 1999-10-07 US US09/413,858 patent/US6613331B1/en not_active Expired - Fee Related
- 1999-11-30 GR GR990403104T patent/GR3032010T3/el unknown
-
2000
- 2000-06-14 GR GR20000401362T patent/GR3033675T3/el not_active IP Right Cessation
- 2000-07-26 JP JP2000225341A patent/JP3328644B2/ja not_active Expired - Fee Related
- 2000-12-11 JP JP2000376159A patent/JP3418171B2/ja not_active Expired - Fee Related
-
2001
- 2001-09-24 NO NO20014624A patent/NO315905B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK283089B6 (sk) | Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie | |
| US5747294A (en) | Compositions and methods for the prevention and diagnosis of lyme disease | |
| IE83320B1 (en) | Vaccine against lyme disease | |
| Sadziene et al. | A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein | |
| US5807685A (en) | OspE, OspF, and S1 polypeptides in Borrelia burgdorferi | |
| MX2010010614A (es) | Composiciones, metodos y kits. | |
| US5911996A (en) | 43 Kd protein vaccine and method for the production thereof | |
| AU673912B2 (en) | Vaccine against lyme disease | |
| IE83340B1 (en) | Vaccine against lyme disease |